Evidence map›Paper›PMID 27709905›Full record

ArticleAnalytical chemistry2016

Complete Molecular Weight Profiling of Low-Molecular Weight Heparins Using Size Exclusion Chromatography-Ion Suppressor-High-Resolution Mass Spectrometry.

Joseph Zaia, Kshitij Khatri, Joshua Klein, Chun Shao, Yuewei Sheng, Rosa Viner

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. [Advances in heparin structural analysis by chromatography technologies].Se pu = Chinese journal of chromatography · 2023
    Review
  2. Isolation and Compositional Analysis of Glycosaminoglycans.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. glypy: An Open Source Glycoinformatics Library.Journal of proteome research · 2019
    Article
  13. Article
  14. Article
  15. Recombinant Heparin-New Opportunities.Frontiers in medicine · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Joseph ZaiaCenter for Biomedical Mass Spectrometry, Department of Biochemistry, Boston University Medical Campus , 670 Albany Street, Boston, Massachusetts 02118, United States.
Kshitij KhatriCenter for Biomedical Mass Spectrometry, Department of Biochemistry, Boston University Medical Campus , 670 Albany Street, Boston, Massachusetts 02118, United States.
Joshua KleinCenter for Biomedical Mass Spectrometry, Department of Biochemistry, Boston University Medical Campus , 670 Albany Street, Boston, Massachusetts 02118, United States.
Chun ShaoCenter for Biomedical Mass Spectrometry, Department of Biochemistry, Boston University Medical Campus , 670 Albany Street, Boston, Massachusetts 02118, United States.
Yuewei ShengCenter for Biomedical Mass Spectrometry, Department of Biochemistry, Boston University Medical Campus , 670 Albany Street, Boston, Massachusetts 02118, United States.
Rosa VinerThermo Fisher Scientific , San Jose, California 95134, United States.
Boston University · USBoston Medical Center · USThermo Fisher Scientific (United States) · US

Funding

Mass Spectrometry Resource for Biology and MedicineP41GM104603 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2012 to 2017
$10.4M
Software for automated interpretation of heparan sulfate tandem mass spectraR21HL131554 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2015 to 2016
$761k
Quantitative profiling of glycosaminoglycans from breast tumor tissue arraysR21CA177479 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2014 to 2016
$712k
A Thermo-Fisher Scientific Q-Exactive HF Mass Spectrometry SystemS10OD021651 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2016 to 2016
$580k
NCI NIH HHS R21 CA177479NHLBI NIH HHS R21 HL131554NIGMS NIH HHS P41 GM104603NIH HHS S10 OD021651
6 · The paper itself

Abstract

Low-molecular weight heparins (LMWH) prepared by partial depolymerization of unfractionated heparin are used globally to treat coagulation disorders on an outpatient basis. Patent protection for several LMWH has expired and abbreviated new drug applications have been approved by the Food and Drug Administration. As a result, reverse engineering of LMWH for biosimilar LMWH has become an active global endeavor. Traditionally, the molecular weight distributions of LMWH preparations have been determined using size exclusion chromatography (SEC) with optical detection. Recent advances in liquid chromatography-mass spectrometry methods have enabled exact mass measurements of heparin saccharides roughly up to degree-of-polymerization 20, leaving the high molecular weight half of the LMWH preparation unassigned. We demonstrate a new LC-MS system capable of determining the exact masses of complete LMWH preparations, up to dp30. This system employed an ion suppressor cell to desalt the chromatographic effluent online prior to the electrospray mass spectrometry source. We expect this new capability will impact the ability to define LMWH mixtures favorably.

Indexed as

Ammonium HydroxideBiosimilar PharmaceuticalsChromatography, GelDalteparinEnoxaparinMass SpectrometryMolecular WeightAmmonium HydroxideBiosimilar PharmaceuticalsDalteparinEnoxaparin

Identifiers

PMID27709905
PMCPMC5111364
OpenAlexW2529025896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.